All In Biotech

Drug Trial Radar · NCT05473910

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Jun 1, 2026

Study completion Jun 2028

Sponsor

Lead sponsor
TScan Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD

Conditions

  • AML
  • MDS

Interventions

  • SOC + TSC-101Drug

    HA-2 positive or HA-1 negative

  • ControlOther

    SOC alone

  • SOC + TSC-100Drug

    HA-1 positive

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of dose limiting toxicitiesTime frame: 2 years
  2. Occurrence of adverse eventsTime frame: 2 years

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of Colorado - Anschutz Cancer Center

    Aurora, Colorado

  • SCRI - Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale

    New Haven, Connecticut

  • Memorial Cancer Institute

    Hollywood, Florida

  • Moffitt Cancer Institute

    Tampa, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Johns Hopkins University

    Baltimore, Maryland

  • Mass General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute - Hematology/Oncology

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Columbia University

    New York, New York

  • Mount Sinai

    New York, New York

  • University North Carolina

    Chapel Hill, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • SCRI - TriStar Bone Marrow Transplant

    Nashville, Tennessee

  • St. David's South Austin Medical Center

    Austin, Texas

  • Baylor University Medical Center

    Dallas, Texas

  • MD Anderson

    Houston, Texas

  • Froedert and Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.